Qed Therapeutics, A Bridgebio Company

This Phase 3 study tested whether the drug infigratinib could help children with achondroplasia (the most common form of dwarfism) grow faster. The trial involved 114 children and teenagers aged 3 to 18 who took either the drug or a placebo. Researchers measured changes in height…

This study tested whether a daily oral medication called infigratinib could safely help children with achondroplasia grow taller. It involved 84 children aged 3-11 who had previously participated in a related study. Researchers measured growth rates, safety, and how the drug move…